Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” hormones are chemically identical to the hormones produced by the human body (usually 17β‑estradiol and progesterone).
• “Standard” or conventional HRT often uses synthetic hormones or animal‑derived mixtures (for example, conjugated equine estrogens like Premarin or synthetic progestins such as medroxyprogesterone acetate/Provera).
• There is no convincing evidence that compounded bioidentical hormone preparations are safer or more effective than FDA‑approved HRT; FDA‑approved bioidentical products (estradiol, micronized progesterone) offer regulated dosing and quality.

More detail, in plain terms

1. What “bioidentical” means

• Bioidentical hormones have the same molecular structure as human hormones (e.g., estradiol, progesterone). They are usually synthesized from plant precursors (yams or soy).
• “Bioidentical” can refer to FDA‑approved products (micronized progesterone, estradiol) or to compounded mixtures made by pharmacies that customize doses/creams/pellets.

1. What “standard” HRT means

• Conventional HRT includes single‑ingredient, FDA‑approved estrogens and progestogens. Some are bioidentical (estradiol, micronized progesterone); others are not (conjugated equine estrogens like Premarin, or synthetic progestins like medroxyprogesterone/Provera).

1. Regulation and quality

• FDA‑approved products are standardized, tested for dose and purity, and have clinical trial data on benefits/risks. Examples: Estrace (oral estradiol), Vivelle‑Dot/Alora/Climara (estradiol patches), Vagifem or Estring (local vaginal estradiol), Prometrium (micronized progesterone), Bijuva (combined estradiol + progesterone pill).
• Compounded bioidentical hormone therapy (custom creams, troches, pellets) is not FDA‑approved, can vary in dose and purity, and lacks large clinical trials proving superior safety or effectiveness. The FDA and medical societies have warned about misleading claims.

1. Safety and effectiveness

• Most risks (breast cancer, venous thromboembolism, stroke, cardiovascular effects) are associated with hormone type, dose, route, and duration, not the marketing label “bioidentical.”
• Some evidence suggests differences by type/route: for example, transdermal estradiol patches may carry lower VTE risk than oral estrogens; micronized progesterone may have a more favorable metabolic and possibly breast/cardiovascular profile than some synthetic progestins, but data are still evolving.
• Compounded products can give unpredictable blood levels and are not proven safer.

1. Testing and dosing

• Saliva hormone tests promoted by some compounding pharmacies are unreliable for guiding menopause treatment. Dosing is usually guided by symptoms and, sometimes, serum levels when clinically appropriate.

Practical recommendations

• Talk with your clinician about goals, medical history, and risk factors (personal/family history of breast cancer, blood clots, heart disease).
• Prefer FDA‑approved products first for predictable dosing and safety data. If you want “bioidentical” hormones, ask about FDA‑approved estradiol products and micronized progesterone (Prometrium) or the combined pill Bijuva (estradiol + progesterone).
• If you have higher clot risk, discuss transdermal estradiol (Vivelle‑Dot, Climara, Alora) which may reduce VTE risk compared with oral estrogens.
• If you have a uterus, you still need a progestogen (micronized progesterone or a progestin) to prevent endometrial hyperplasia. Prometrium is the common micronized progesterone brand.
• If you’re considering compounded BHRT, use a reputable compounding pharmacy that follows USP standards and provides batch testing; ask why the compounded option is preferred and for evidence.

Guidance sources

• Professional societies (North American Menopause Society, Endocrine Society) and the FDA recommend caution with compounded bioidentical products and favor evidence‑based, FDA‑approved therapies.

If you want, tell me:

• your main symptoms, age, and health history (esp. clotting, breast cancer, heart disease) and I can outline specific options and what to discuss with your clinician.